MaxCyte Confirms Appointment of Maher Masoud as President, Chief Executive Officer and Director

January 2, 2024

https://www.globenewswire.com/news-release/2024/01/02/2802418/0/en/MaxCyte-Confirms-Appointment-of-Maher-Masoud-as-President-Chief-Executive-Officer-and-Director.html

ROCKVILLE, Md., Jan. 01, 2024 (GLOBE NEWSWIRE) — MaxCyte, Inc., (NASDAQ:MXCT; LSE:MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and innovative bioprocessing applications, is pleased to confirm the appointment of Maher Masoud as President and Chief Executive Officer of MaxCyte effective as of January 1, 2024. In addition, Mr. Masoud now serves as a director on MaxCyte’s Board of Directors.

Read more at globenewswire.com

Related news for (MXCT)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.